MedTrace Logo

Safety and Immunogenicity of a Plasmid HIV Vaccine in HIV Uninfected Adults

NCT00249106 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2013-02-11

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and immune response to a investigational DNA Plasmid HIV vaccine, ADVAX e/g + ADVAX p/n-t (ADVAX), at three different dosage levels, in adults who are not infected with HIV.

Conditions

  • HIV Infection

Interventions

BIOLOGICAL

ADVAX

Sponsors & Collaborators

  • Aaron Diamond AIDS Research Center

    collaborator OTHER

  • University of Rochester

    collaborator OTHER

  • International AIDS Vaccine Initiative

    lead NETWORK

Principal Investigators

  • David Ho, MD · Aaron Diamond AIDS Research Center

  • Michael Keefer, MD · University of Rochester

  • Soe Than, MD · International AIDS Vaccine Initiative

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-12-31
Primary Completion
2005-10-31
Completion
2005-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00249106 on ClinicalTrials.gov